OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 601 - 610 of 796 studies

Cancer and neoplasms

A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

CHampioning shared decisiOn-making In Craniofacial carE (CHOICE)

Neurological

A Phase 2, Double-Blind Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Apitegromab in Subjects <2 Years Old With Spinal Muscular Atrophy (SMA) (OPAL)

Oral and Gastrointestinal

A Phase IIb, Multicenter, Double-Blind, Placebo-Controlled Induction Study With An Active Treatment Extension To Assess The Efficacy, Safety, And Pharmakokinetics Of Ro7837195 In Patients With Moderately To Severely Active Ulcerative Colitis (GA45977 (SUNCREST))

Respiratory

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Efficacy of Caveolin-1-ScaffoldingProtein-Derived Peptide (LTI-03) in Patients with Idiopathic Pulmonary Fibrosis (RENEW)

Cancer and neoplasms

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of Enzomenib (DSP-5336) in Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation (DSP-5336-101)

A prospective, real-world registry of acute myeloid leukaemia patients in the United Kingdom

Neurological

Long-term extension study to evaluate the safety and efficacy of riliprubart (SAR445088) in participants with chronic inflammatory demyelinating polyneuropathy (CIDP) (LTS17261 (VITALIZE Extension))

Cancer and neoplasms

An open-label, multicentre, integrated Phase 1 & 2 study to evaluate the safety, tolerability, radiation dosimetry and anti-tumour activity of Lutetium (177Lu) rhPSMA-10.1 injection in men with metastatic castrate-resistant prostate cancer

Cancer and neoplasms

A Master Protocol for an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants with Locally Advanced Resectable Gastroesophageal Adenocarcinoma (GEMINI-PeriOp GC)